AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2020
Dec 17, 2020
30604_dirs_2020-12-17_9c2bd566-8564-4a0b-9982-f5f0f6e67147.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-12-15
Reporting Person: Sinha Uma (Chief Scientific Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-12-15 | Stock Option (Right to Buy) | $3.07 | A | 8912 | Acquired | 2030-04-01 | Common Stock (8912) | Direct |
| 2020-12-15 | Stock Option (Right to Buy) | $3.07 | A | 10832 | Acquired | 2030-07-20 | Common Stock (10832) | Direct |
| 2020-12-15 | Stock Option (Right to Buy) | $42.80 | A | 5717 | Acquired | 2030-09-29 | Common Stock (5717) | Direct |
Footnotes
F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio.
F2: 3,342 shares subject to the stock option were vested as of the date of acquisition, 186 shares shall vest on January 1, 2021, and 5,384 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
F3: 4,062 shares subject to the stock option were vested as of the date of acquisition, 226 shares shall vest on January 1, 2021, and 6,544 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
F4: 2,144 shares subject to the stock option were vested as of the date of acquisition, 119 shares shall vest on January 1, 2021, and 3,454 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.